BioSpace News Archive

Eli Lilly and Company (NYSE: LLY) today announced additional details on its SARS-CoV-2 neutralizing antibody programs – including interim data on combination therapy in recently diagnosed patients with mild-to-moderate COVID-19 – and plans to make these therapies broadly available to patients.

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) to increase the maximum allowable dose of 60 mg with Palynziq® (pegvaliase-pqpz) Injection for treatment of adults with Phenylketonuria (PKU).

New research in the October 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds the rate of bone mineral density (BMD) testing in people with prostate cancer undergoing androgen deprivation therapy (ADT) has improved in recent years, but remains low

Ambu Inc., the world leader in single-use endoscopes, announced that it has been awarded a national single-use endoscopy contract in the category of Single-Use Endoscopes with a major U.S. Group Purchasing Organization.

Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced the pricing of a registered direct offering of $5.1 million of its common stock and warrants to purchase shares of common stock in a concurrent private placement.

Imagin Medical (CSE:IME) (OTCQB:IMEXF) (Frankfurt & Stuttgart Symbol:DPD2) (“Imagin” or the “Company”) today announced that it has selected Lighthouse Imaging (“Lighthouse”) as the contract manufacturer for the Company’s i/Blue Imaging System.

Stephen A. Rosenberg, MD, PhD has been named the Philadelphia Academy of Surgery’s 2020 Samuel D. Gross Prize winner. The prize is accompanied by a $5,000 monetary award and will be presented on November 2, 2020.

The effects of screens on children’s sleep have been a focus of public health concern for decades.

LION Eye Group, a network of independent optometry practices that utilizes various key initiatives and protocols across strategic and non-clinical operational disciplines to increase provider profitability, entered into a Vendor Agreement with WestGroupe Optical, Inc.

Propella Therapeutics Inc. (Propella), a leader in the development of innovative best-in-class prescription products, today announced the issuance of a U.S. patent for a new drug treatment for metastatic prostate cancer.